3D organotypic cell structures for drug development and Microorganism-Host interaction research by Zubareva, E. V. et al.
3D organotypic cell structures for drug development 
and Microorganism-Host interaction research
Ekaterina V. Zubareva1, Sergey V. Nadezhdin1,2, Natalia A. Nadezhdina3,  
Veronika S. Belyaeva1, Yuriy E. Burda1, Tatyana V. Avtina1, Oleg S. Gudyrev1,  
Inga M. Kolesnik1, Svetlana Yu. Kulikova1, Mikhail O. Mishenin1
1 Belgorod State National Research University, 85 Pobedy St., Belgorod 308015, Russia
2 Research Laboratory of Cellular, Assisted Reproductive and DNA Technologies of Belgorod State National Research University, 85 Pobedy St., 
Belgorod 308015, Russia
3 Children’s Regional Clinical Hospital, 44 Gubkin St., Belgorod 308036, Russia
Corresponding author: Ekaterina V. Zubareva (zubareva@bsu.edu.ru)
Academic editor: Mikhail Korokin  ♦  Received 16 December 2020  ♦  Accepted 3 March 2021  ♦  Published 31 March 2021
Citation: Zubareva EV, Nadezhdin SV, Nadezhdina NA, Belyaeva VS, Burda YuE, Avtina TV, Gudyrev OS, Kolesnik IM, Kulikova 
SYu, Mishenin MO (2021) 3D organotypic cell structures for drug development and Microorganism-Host interaction research. 
Research Results in Pharmacology 7(1): 47–64. https://doi.org/10.3897/rrpharmacology.7.62118
Abstract
Introduction: The article describes a new method of tissue engineering, which is based on the use of three-dimensional 
multicellular constructs consisting of stem cells that mimic the native tissue in vivo – organoids.
3D cell cultures: The currently existing model systems of three-dimensional cultures are described.
Characteristics of organoids and strategies for their culturing: The main approaches to the fabrication of 3D cell 
constructs using pluripotent (embryonic and induced) stem cells or adult stem cells are described.
Brain organoids (Cerebral organoids): Organoids of the brain, which are used to study the development of the human 
brain, are characterized, with the description of biology of generating region-specific cerebral organoids.
Lung organoids: Approaches to the generation of lung organoids are described, by means of pluripotent stem cells 
and lung tissue cell lines.
Liver organoids: The features of differentiation of stem cells into hepatocyte-like cells and the creation of 3D hepatic 
organoids are characterized.
Intestinal organoids: The formation of small intestine organoids from stem cells is described.
Osteochondral organoids: Fabrication of osteochondral organoids is characterised.
Use of organoids as test systems for drugs screening: The information on drug screening using organoids is provided.
Using organoids to model infectious diseases and study adaptive responses of microorganisms when interacting 
with the host: The use of organoids for modeling infectious diseases and studying the adaptive responses of microor-
ganisms when interacting with the host organism is described.
Conclusion: The creation of three-dimensional cell structures that reproduce the structural and functional character-
istics of tissue in vivo, makes it possible to study the biology of the body’s development, the features of intercellular 
interactions, screening drugs and co-cultivating with viruses, bacteria and parasites.
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unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Introduction
A new tissue engineering technique proposed by scien-
tists is based on using three-dimensional (3D) multicellu-
lar constructs consisting of stem cells which mimic tissue 
in vivo – organoids (Lancaster and Knoblich 2014b; Yin 
et al. 2016). Due to the incredible potential of 3D cell 
systems applying to study human biology and disease, or-
ganoids were picked by the Nature Methods as a Method 
of the Year in 2017 (Method of the year 2017: Organoids, 
2018), and they still remain an advanced method in stem 
cells research (Devarasetty et al. 2018; Marsoner et al. 
2018), which is confirmed by an annual growth in the 
number of publications (Fig. 1).
Organoids are a new “model organism” to study com-
plex disease phenotypes and genetic diversity among 
individuals using autologous tissues from patients (Leh-
mann et al. 2019). The use of bioengineered three-dimen-
sional tissue and tumor organoids becomes today the gold 
standard of organ and tissue replication ex vivo (Lancas-
ter and Knoblich 2014b; Mills and Estes 2016; Skardal 
et al. 2016a; Devarasetty et al. 2018). Organoids make it 
possible to carry out research in 3D environment in com-
parison with traditional 2D cell cultures, which possibly 
could be limiting when trying to reproduce physiological 
interactions at the tissue level (Pampaloni et al. 2007).
Cells, as a part of a tissue, communicate with the neigh-
bouring cells and extracellular matrix (ECM) via biochemi-
cal and mechanical signals. Cell-cell and cell-extracellular 
matrix interactions create a tissue specific 3D communica-
tion network which provides homeostasis. The key events 
in a cell cycle, such as adhesion, migration, proliferation 
and apoptosis, are regulated by the principles of tissue or-
ganization determined by tissue morphofunctional features. 
Thus, 3D cell cultures which replicate physiological reac-
tions between cells and extracellular matrix are able to mi-
mic specificity of different real tissues better than common 
two-dimensional cell cultures (Pampaloni et al. 2007).
Today there is evidence that organoids can be widely 
applied both in research and in pharmacological scree-
ning of advanced therapeutic drugs as pre-clinical diag-
nostic models, which makes them essential instruments in 
experimental medicine (Devarasetty et al. 2018).
3D cell cultures
Currently there are several 3D culture model systems. Sp-
heroids are clusters of cells grown in suspension, which can 
be formed either from cell lines (homotypic spheroids) or 
from dissociated tumor tissues (heterotypic spheroids) (Is-
higuro et al. 2017; Es et al. 2018). Spheroids can be ob-
tained from cells of the same type or as a result of co-cul-
tivation (mono- and multicellular spheroids, respectively) 
(Pampaloni et al. 2007). Such structures usually lack any or-
ganization and consist of undifferentiated cells, which is the 
reason to use these models to study stem cells (Baker 2018).
Spheroids can be easily obtained by cell aggregati-
on using hanging drop technique, or when culturing in 
non-adhesive round-bottom plates (Loessner et al. 2010) 
and when cultivating cells in rotating-wall vessels (bio-
reactors). The main advantage of spheroids is that cell 
aggregation occurs without scaffolds. The cell spheroid 
system is often the choice for therapeutic biomedical re-
search. They are applied in biotechnology and can be used 
for high-throughput screens in pharmacological studies. 
Simple spherical geometry makes it relatively easy to si-
mulate dynamic processes, such as growth and invasion 
of solid tumors (Pampaloni et al. 2007).
Polarized epithelial tissue models are obtained by cul-
turing non-transformed immortalized epithelial cell lines 
in three-dimensional conditions, e.g. growing MDCK 
cells or mammary epithelial MCF-10A cells as polarized 
monolayers on the surfaces of microporous membranes 
or as hollow spherical monolayers in ECM gels. Tissue 
analogues of such suborganic structures are common to 
most epithelial organs and are known as acini in mam-
mals’ tissues. More complicated epithelial constructs, 
such as skin, are formed from 3D cultures on the basis of 
membrane inserts or using microscale materials, such as 
supporting fibre meshes (Pampaloni et al. 2007). At the 
same time, large cell aggregates require careful control of 
gas exchange and diffusion of soluble nutrients and che-
mical substances (Pampaloni et al. 2007).
Figure 1. The number of search results in the Google Scholar 
system.
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Tissues can be manufactured using hydrogels, which 
inoculate cells during matrix formation, or using scaf-
folds, onto which cells are directly seeded (Loessner et 
al. 2010; Devarasetty et al. 2018). Engineering of 3D 
cell constructs based on biomaterials has advantages 
over the scaffold free approach, since biomaterials used 
as scaffolds allow better control of organoids and their 
microenvironment, including stiffness, ECM components 
and spatial organization of different cell types (Yamada 
et al. 2012). Biomaterials used to manufacture organoids 
are characterized by different porosity, levels of stiffness, 
cellular-adhesive motifs and viscosity, any of which can 
effect cellular morpho-physiological properties and tis-
sue functioning on the whole (Skardal et al. 2012; Beck 
et al. 2013). Biomaterials used for manufacturing orga-
noids mostly include collagen, hyaluronic acid, gelatine, 
and chitosan (Devarasetty et al. 2018). Hydrogels used 
as biomaterials can be used in bioproduction approaches, 
such as bioprinting, and they are focused on improving 
design and production when fabricating organoids and 
organs. In addition, there are hybrid approaches, such as 
the inclusion of aggregated tissue spheroids in hydrogels 
to form larger multicolonies and highly functional tissue 
construct models (Devarasetty et al. 2018).
Among strategies to form organoid platforms are the 
use of microfluidic technology which makes it possible to 
combine tissue organoids of different origin to generate a 
full body-on-a-chip. Using this system-biology-based ap-
proach, significant advances can be made in the drug de-
velopment and personalized regenerative medicine (Sung 
et al. 2013; Devarasetty et al. 2018).
Organ-on-a-chip systems are miniature microfluidic 
3D models of human tissues and “organs” designed to re-
produce the most important biological and physiological 
parameters of their in vivo analogs. A number of organoid 
models can be combined using microfluidics, taking into 
account the organization of structures in vivo, thus provi-
ding the ability to analyze interorgan interactions (Fukuda 
et al. 2006; Loessner et al. 2010; Skardal et al. 2012; Ya-
mada et al. 2012; Messner et al. 2013; Sung et al. 2013; 
Bhise et al. 2014; Friedman et al. 2015; Purwada et al. 
2015; Peng et al. 2016; Skardal et al. 2016b; Devarasetty 
et al. 2017; Mazzocchi et al. 2017; Purwada and Singh 
2017; Zhang et al. 2017). Furthermore, considerable at-
tention in this area is paid to the construction of biomi-
metic models of organs (Moraes et al. 2012; Bhatia and 
Ingber 2014; Esch et al. 2015). It is increasingly recogni-
zed that the inclusion of biosensing will enable in situ mo-
nitoring of the status of these miniature organs (Wikswo 
et al. 2013; Zhang and Khademhosseini 2015).
Characteristics of organoids and 
strategies for their culturing
Taking into account a large number of fabrication techni-
ques, the term “organoid” is used to define organ-specific 
3D cultures (Yamada et al. 2012).
Organoids can be characterized as 3D constructs con-
taining tissue-specific cells that perform the function 
of restoring the cellular microenvironment and inclu-
de structures of the extracellular matrix or biomaterials 
(Lancaster and Knoblich 2014b). Each organ-specific 
3D construct – organoid, as a rule, includes many types 
of cells, and the ratio of cell types is optimized in order 
to induce the organoid function, which can be investiga-
ted using organ-specific biomarkers or other techniques 
(Skardal et al. 2016a; Devarasetty et al. 2018).
Pluripotent (embryonic or induced) stem cells or adult 
stem cells obtained from various sources can be used to 
establish organoids (Lancaster and Knoblich 2014b; de 
Souza 2018). Under conditions of growth in a three-di-
mensional environment, stem cells of different origins 
(hESCs/hiPSCs/hAdSCs) get self-organized into orga-
noids due to the proliferation and differentiation of va-
rious types of cells, which suggests that they are identical 
to their analog in vivo (Drost and Clevers 2017) if at least 
some of the functions of the organ are replicated (Huch 
and Koo 2015). Some methods of establishing organoids 
from pluripotent stem cells imply the communication of 
minimal information to the cells for differentiation (apart 
from providing them with the necessary conditions for 
growth and nutrients), which contributes to the imple-
mentation of an internal program of self-organization 
and, probably, mediates the launch of random processes 
necessary for tissue formation (de Souza 2018) or, on the 
contrary, organoids are cultivated in a solid matrix in or-
der to reproduce the natural structural characteristics and 
cellular composition of native tissues (Baker 2018).
Two main approaches to the formation of organoids 
from stem cells were first described in 2009.
Sato et al. characterized the conditions for unlimited 
3D expansion of organotypic structures in vitro from one 
Lgr5 + ISCs obtained from intestinal crypts (Sato et al. 
2009). These organoids contained all types of intestinal 
epithelial cells and were structured into proliferating 
crypts and differentiated villi, thus preserving the archi-
tecture of the intestine in vivo (Sato et al. 2009). Additio-
nally to Wnt/R-spondin, the researchers included epider-
mal growth factor (EGF) in the cocktail, noggin (which 
inhibits BMP) and an artificial extracellular matrix enri-
ched with laminin (provided by Matrigel) for the succes-
sful propagation of organoids derived from mouse ISCs 
(Dignass and Sturm 2001; Haramis et al. 2004; Drost and 
Clevers 2017). At the same time, Ootani et al. showed 
another culture of ISCs activated via Wnt (Ootani et al. 
2009). In contrast to the experiments by Sato et al., the 
supply of growth factors to the medium in this culture 
was provided by the underlying stromal component, ra-
ther than by the inclusion of specific growth factors into 
the medium, and the organoids were cultured in collagen 
at the air-liquid interface (Drost and Clevers 2017).
It is important to note that both studies “restored” the 
stem cell niche in vitro either by artificially adding niche 
factors (Noggin, EGF, Wnt, R-spondin) (Sato et al. 2009) 
or by including the mesenchymal component into the cul-
ture (Ootani et al. 2009; Drost and Clevers 2017).
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The Sasai lab started using pluripotent stem cells to 
create various components of the central nervous sys-
tem. They differentiated human pluripotent stem cells 
into self-organizing three-dimensional aggregates, 
which were named SFEBq (serum-free floating culture 
of embryoid body-like aggregate with quick reaggrega-
tion) which contained apically-basally polarized cortical 
tissue (Eiraku et al. 2008; Eiraku et al. 2011; Marsoner 
et al. 2018).
The technology for organoids establishing developed 
from cultures of embryoid bodies, which are 3D aggre-
gates of stem cells, self-organizing to form various tissues 
in vitro (Huch and Koo 2015).
Organoid establishing process involves the isolation 
of tissue of interest from the body and its careful disso-
ciation to release a population of progenitor cells, either 
tissue-specific adult stem cells or pluripotent embryonic 
stem cells, usually with no isolation and purification of 
stem cells required (Sato et al. 2011). Induced pluripotent 
cells can be used as an alternative. Usually, cells are im-
mersed in a 3D Matrigel matrix, which contains laminin, 
entactin, proteoglycans, and collagen IV (Es et al. 2018). 
Cells are fed with enriched media if they originate from 
mesodermal tissues (for instance, intestines and liver) or 
with depleted media if they come from neuroectodermal 
tissues (for example, brain and retina). In both cases, the 
medium should contain tissue-specific niche growth fac-
tors that provide controlled differentiation and tissue or-
ganization (Lancaster and Knoblich 2014b). For intestinal 
tissues, these are epidermal growth factor, morphogenetic 
proteins Noggin and WNT3, and the WNT signal ampli-
fier R-spondin (Dutta et al. 2017).
For nerve tissues, pluripotent stem cells must first un-
dergo neuronal induction and then it becomes possible to 
form organoids of specific brain regions using appropriate 
factors (Yin et al. 2016).
It is known that organoids obtained from adult stem 
cells can keep native organ characteristics and genetic 
stability for a long time (Behjati et al. 2014; Huch et al. 
2015; Drost and Clevers 2017), which has been proven 
by multiple passaging (Sato et al. 2011; Huch et al. 2015) 
and complete genome sequencing of some organoids at 
the beginning and at the end of culturing (Behjati et al. 
2014; Huch et al. 2015; Drost and Clevers 2017).
Since the first organoids were obtained from adult 
stem cells – Lgr5 + stem cells, which were used to es-
tablish the so-called “mini-intestine”, phenocopying the 
epithelium of intestinal crypts and villi (Sato et al. 2009), 
organoids have been established from tissues of various 
organs and structures of the body (Clevers 2016; Rios 
and Clevers 2018) – mouse and human liver, pancreas, 
stomach, fallopian tubes, prostate, taste buds, salivary 
gland, kidneys, breast, lungs and brain (Barker et al. 
2010; Huch et al. 2013a; Huch et al. 2013b; Chua et al. 
2014; Karthaus et al. 2014; Ren et al. 2014; Boj et al. 
2015; Bartfeld et al. 2015; Kessler et al. 2015; Huch et 
al. 2015; Maimets et al. 2016; Drost and Clevers 2017; 
Ng-Blichfeldt et al. 2019).
It has already become apparent that the study of or-
ganoids is the most developing field in cell biology and 
tissue engineering (Marsoner et al. 2018).
There are several characteristics of organoids that de-
termine their value as test systems (models). They can be 
obtained from both healthy and damaged tissues of ani-
mals and humans, making it possible to simulate tissue 
homeostasis, recovery, and various pathological proces-
ses. Organoids can be cultured for an indefinitely long 
period of time in a medium with a given composition, 
remaining stable and preserving tissue features, making 
it possible to accurately scale the experimental material 
corresponding to the source tissue. And finally, organoids 
are suitable for the implementation of almost all cellular 
biological and molecular technologies that are used on 
cell lines and can be transplanted into the body of ani-
mals for the study of human diseases in vivo (Rios and 
Clevers 2018). It should be noted that the technology for 
the establishing of organoids is universal. For their culti-
vation, both small fragments of tissue obtained by biopsy 
and samples obtained by surgical excision can be used 
(Drost and Clevers 2017). In addition, organoids provi-
de a unique opportunity to model human organogenesis, 
which is not available in traditional experimental models 
(Qian et al. 2016).
Brain organoids (Cerebral 
organoids)
The complexity of the human brain structure compli-
cates the study of its disorders using model organisms, 
emphasizing the need to create an in vitro model of hu-
man brain development (Lancaster et al. 2013; Lancas-
ter and Knoblich 2014a). Brain organoids represent a 
completely new platform for the study of human brain 
development (Qian et al. 2016; Quadrato et al. 2016). 
Generation of region-specific brain organoids (Muguru-
ma et al. 2015; Sakaguchi et al. 2015; Jo et al. 2016; 
Qian et al. 2016) further facilitates the modeling of spe-
cific areas of the brain. Recently, tangential migration 
of cortical interneurons has been replicated in vitro by 
fusion of organoids that reproduce the cortex (hCO) 
and MGE or subpallium (hMGEO) of the brain to allow 
functional integration (Bagley et al. 2017; Birey et al. 
2017; Xiang et al. 2017).
It was revealed that the developing neocortex is orga-
nized into separate compartments of proliferative proge-
nitors, the ventricular zone (VZ) and subventricular zone 
(SVZ), which give rise to the outer neuronal layers in the 
cortical plate (CP). VZ and SVZ contain different types 
of neuronal progenitors: apical radial glial cells (aRG) 
in VZ and basal radial glial cells (bRG), intermediate 
progenitors (IPs) and transint amplifying cells in SVZ. 
The key factor contributing to the growth of the human 
neocortex is the expansion of SVZ progenitors (Watana-
be et al. 2017).
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The development of the mammalian brain begins with 
the expansion of the neuroepithelium, followed by the gene-
ration of radial glial stem cells (RGs) (Lancaster et al. 2013).
Lancaster et al. characterized the formation of neuroec-
toderm from embryoid bodies. The neuroectodermal 
tissue was then maintained in 3D culture and placed in 
Matrigel drops to provide a scaffold for more complex 
tissue growth. Matrigel drops were then transferred to a 
bioreactor to enhance nutrient absorption. At the initial 
stages (15–20 days), cerebral organoids formed a neuroe-
pithelium surrounding a fluid-filled cavity resembling a 
ventricle with a characteristic apical localization of neural 
specific N-cadherin (NCAD). After being cultured for 2 
months in the bioreactor, organoids became the forma-
tions consisting of heterogeneous tissues, showing the 
structures resembling cortex, choroid plexus, retina, and 
meninges. Cerebral organoids of similar morphology and 
composition can be established from both embryonic 
stem cells (ESCs) and induced human pluripotent stem 
cells (Lancaster et al. 2013).
Several protocols have been described for the cultivati-
on of cerebral organoids derived from hPSCs that precede 
the emergence of basal progenitors. Watanabe et al. sho-
wed that enhanced stimulation of the STAT3 pathway in-
creased the production of basal progenitors, improved the 
formation and separation of neural layers, and promoted 
astrogliogenesis (Watanabe et al. 2017).
Most cortical region-specific organoids are formed un-
der the influence of small pathway modulators, including 
SMAD signaling inhibitors, required to prevent mesoderm 
and endoderm differentiation (Eiraku et al. 2008; Ka-
doshima et al. 2013; Mariani et al. 2015; Paşca et al. 2015; 
Qian et al. 2016; Iefremova et al. 2017; Xiang et al. 2017).
Some studies examined the migration of neuronal 
cells, which reproduce the migration of cortical inhibitory 
interneurons originating from the ventral part of the fore-
brain by fusion of organoids originating from the dorsal 
and ventral regions of the brain (Bagley et al. 2017). It 
was also shown that microglia, originating from the me-
soderm and being one of the key players in neuronal de-
velopment, can also develop within the cerebral organoid 
model (Ormel et al. 2018).
Li et al. showed that the PTEN-AKT signaling pathway 
is involved in the formation of human cerebral organoids 
that are enlarged and exhibit surface folding. At the same 
time, removal of PTEN is accompanied by an increase 
in neuronal progenitors proliferation and the formation of 
larger and folded cerebral organoids (Li et al. 2017).
There is evidence of growth factors being involved in the 
regulation of expansion and folding of the cortex, including 
PDGF-D (platelet-derived growth factor D) (Li et al. 2017).
Xiang et al. developed a technque for differentiating 
hESCs into thalamic brain organoids (hThOs), manufac-
tured a 3D model to reproduce reciprocal thalamic-cor-
tical projections (TC projections) between the thalamus 
and cortex by fusion of hThOs and hCOs, resulting in the 
formation of united thalamo-cortical organoids (hThCOs) 
(Xiang et al. 2019).
Lung organoids
Human lung organelles (HLOs) are composed of basal 
cells, ciliated epithelial cells, goblet cells, and CC10-se-
creting club cells (Sachs et al. 2019).
The method of lung lineages formation due to stimula-
tion of differentiation of hPSCs, both hESCs and iPSCs, 
is described (Kadzik and Morrisey 2012; Longmire et al. 
2012; Mou et al. 2012; Wong et al. 2012; Ghaedi et al. 
2013; Huang et al. 2014; Dye et al. 2015); however, most 
studies were performed on 2D cultures. Dye et al. esta-
blished a three-dimensional model of the human lung by 
stimulating human stem cells differentiation, influencing 
several signaling pathways that control organ formation 
during embryonic development. At first, stem cells form 
endoderm, from which lungs, liver and some other inter-
nal organs are formed during embryogenesis. Then, in 
endodermal cultures derived from hPSCs, WNT and FGF 
signaling pathways were activated, and simultaneously 
BMP/TGFβ signaling pathways were inhibited, which 
prevented commitment along the intestinal line, and in-
stead led to the formation of SOX2+ anterior foregut and 
to the rapid formation of SOX2+ anterior foregut 3D sp-
heroidal structures. In order to further restrict the diffe-
rentiation of the foregut spheroids in the direction of the 
pulmonary line by using HHHi conditions during the ge-
neration of foregut spheroids, the expression of NKX2.1 
increased in cells that formed spheroids, and then the 
spheroids were placed for further growth in a medium 
containing FGF10, which enabled them to grow into or-
ganoids. Organoids persisted in culture for over 100 days 
and developed into well-organized proximal-like epithe-
lial structures of the airways, which included many cell 
types found in the proximal lung epithelium, basal cells, 
ciliated cells, and rare club cells. Moreover, the proximal 
airway structures were often surrounded by smooth mus-
cle actin positive mesenchymal tissue. Organoids also 
contained distal-like epithelial cells that expressed proge-
nitor markers, SFTPC/SOX9 and HOPX/SOX9, corres-
ponding to early bipotent alveolar progenitor cells found 
in mice (Desai et al. 2014; Treutlein et al. 2014; Dye et al. 
2015). Obviously, the proximal and distal regions of lungs 
contain different types of epithelial cells which realise va-
rious functions. For instance, basal, secretory and ciliated 
cells in the airways and type-2 alveolar epithelial cells 
(AEC2s), which secrete surfactant and other proteins, and 
sensitive type-1 alveolar epithelial cells (AEC1s), which 
form a large surface in the alveoli, which serves for gas 
exchange with the surrounding capillaries. In addition, 
the outer mesothelial layer and immune cells are impor-
tant populations of lung tissue cells (Tan and Krasnow 
2016; Barkauskas et al. 2017).
During organoids establishing from basal cells obtain-
ed from the trachea or large airways, a medium contai-
ning EGF, CFE (up to 20%) is used for cultivation; human 
fibroblast cell lines, such as MRC5 cells, can be added 
there. Under the standard conditions, organoids contain 
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TRP63+ KRT5+ basal cells, functional ciliated cells, and 
secretory goblet cells (MUC5AC+, MUC5B+) (Danahay 
et al. 2015; Butler et al. 2016; Hild and Jaffe 2016).
It is possible to use organoids formed from human ba-
sal cells for screening cytokines and other proteins that 
could influence the ratio of ciliated cells to secretory cells, 
which is impaired, for example, in chronic asthma (Bar-
kauskas et al. 2017). Epithelial cells and mesenchymal 
stem cells are required to form alveolospheres using AE-
C2s (Barkauskas et al. 2017).
TGF-β activation is known to impair the ability of fi-
broblasts to support the formation of organoids from lung 
epithelial progenitor cells (Ng-Blichfeldt et al. 2019). 
TGF-β is a pleiotropic cytokine that exhibits a variety of 
transcriptional effects by interacting with type I and type 
II TGF-β receptors and subsequent phosphorylation and 
nuclear translocation of Smad2/3. Exposure to TGF-β 
may also interact with the activation of proreductive sig-
naling pathways, including the Wnt/β-catenin signaling 
pathway (Ng-Blichfeldt et al. 2019).
Liver organoids
To replicate liver development in vitro, several scientific 
groups successfully differentiated human iPSCs into he-
patocyte-like cells using a sequential differentiation pro-
tocol based on several chemical inhibitors (Palakkan et al. 
2017; Prior et al. 2019). A different approach was chosen 
in the Suzuki and Hui laboratories, in which they trig-
gered forced expression of the first hepatic transcription 
factors (HNF4a, FOXA1,2,3) (Sekiya and Suzuki 2011) 
or (HNF4a, GATA4 и HNF1B) (Huang et al. 2011) in or-
der to induce direct differentiation of iPSCs into hepato-
cyte-like cells in vitro. However, these approaches were 
implemented under the 2D cell culture conditions. The 
first endeavors to form 3D hepatic organoids were made 
using cultures of the embryonic liver bud by Takebe et 
al.: during the experiment, hepatocytes obtained from iP-
SCs were cultured with umbilical cord mesenchymal stem 
cells (Takebe et al. 2013). Since then, the scheme develo-
ped by Takebe et al. has been modified so that hepatic en-
doderm, mesenchymal and endothelial progenitors are de-
rived from iPSCs (Takebe et al. 2017). In addition, human 
iPSCs can be differentiated by targeting specific signaling 
pathways into cholangiocyte organoids (Sampaziotis et al. 
2015). It is also emphasized that hepatobiliary structures 
containing hepatocytes and cholangiocytes were obtained 
from iPSCs (Vyas et al. 2018; Wu et al. 2019). However, 
a limitation to the use of iPSCs organoids in clinical prac-
tice is their genomic instability resulting from exposure to 
reprogramming factors (Tapia and Schöler 2016).
Intestinal organoids
Organoids can be obtained from two sources of stem 
cells: organ-specific adult stem cells (ASCs) and plu-
ripotent stem cells (PSCs), both induced (iPSCs) and 
embryonic (ESCs) (Rahmani et al. 2019). The use of the-
se approaches makes it possible to obtain 3D structures 
which would have microarchitecture of villi and crypts 
of the small intestine, capable of self-renewal and self-or-
ganization over a long period. Wnt-3a, Epidermal growth 
factor, Noggin and R-spondin are the key components, 
the presence of which in the culture medium is manda-
tory; a medium containing a complex of these factors is 
called WENR medium. The spatio-temporal incorporati-
on of these growth factors into the culture medium regu-
lates the triggering of stem cell niche signaling pathways, 
including Wnt, bone morphogenetic protein (BMP), and 
Notch, which induce ISCs to self-renew, proliferate, and 
differentiate. It was also shown that the inclusion in the 
ENR medium of such additional combinations of compo-
nents as CHIR99021 and valproic acid, or LDN-193189, 
and CHIR99021 has a synergistic effect that contributes 
to the maintenance of Lgr5+ ISCs in a self-renewing and 
undifferentiated state, which leads to the enrichment of 
the culture of ISCs. Whereas a differentiated phenotype 
can be obtained using ENR media supplemented with the 
following pairs of molecules: DAPT and CHIR99021, 
valproic acid and IWP-2, or DAPT and IWP-2. These 
molecules coordinate the action of each other and induce 
the direct differentiation of ISCs into Paneth cells, en-
terocytes and secretory cell lines called goblet cells and 
enteroendocrine cells, respectively. It was demonstrated 
that the addition of DAPT or BMP molecules to the cul-
ture medium is sufficient to stimulate the differentiation 
of ISCs and the generation of multicellular intestinal or-
ganoids. Moreover, some studies have been carried out to 
search for methods to reduce the cost of culture media, 
which reported that the Noggin protein can be replaced 
by LDN-193189, and R-spondin 1 protein can be sub-
stituted by RS-246204 (Liu et al. 2018; Nam et al. 2018; 
Rahmani et al. 2019).
Induced human intestinal organoids (iHIOs) derived 
from pluripotent cells represent a new experimental mo-
del for studying intestinal pathogens (Karve et al. 2017). 
Karve et al. described the in vitro generation of iHIOs 
from pluripotent embryonic stem cells by triggering a 
process that replicated normal differentiation and made it 
possible to get organoids that reproduce tissue of the dis-
tal human small intestine to which E. coli preferentially 
attaches. Organoids have a luminal cavity, a microscopic 
brush border, villi, and crypts. The organoid epithelium 
contains enterocytes and major secretory lines (Paneth 
cells, endocrine cells, and goblet cells), and retains such 
functions as peptide transport and mucus secretion by 
goblet cells. The epithelium is surrounded by a layer of 
mesenchyme, which contains smooth muscle cells and su-
bepithelial fibroblasts. iHIOs have been successfully used 
to study embryonic development, inflammatory bowel di-
sease and infections (Karve et al. 2017).
Organoids obtained through cultivation of adult stem 
cells are formed by harvesting stem cells contained in 
crypts, or by isolating single Lgr5-expressing ISCs of 
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the small intestine or human colon tissue, depending on 
which they are called enteroids or colonoids, respective-
ly (Stelzner et al. 2012). Organoids derived from adult 
stem cells have limitations, such as the absence of me-
senchymal stem cells, including myofibroblasts, endothe-
lial cells, and smooth muscle cells, which could secrete 
growth factors into the medium and thus influence signa-
ling pathway activity and cell proliferation. In this con-
nection, it is imperative to use a cocktail of growth factors 
called WENR for the cultivation of enteroid organoids, 
enteroids (Rahmani et al. 2019).
It is known that the technology of culturing intes-
tinal organoid (mini-gut) is actively used, including 
modeling diseases and therapeutic effects, studying 
interaction of the host and microorganism, delivery 
of biomolecules, biology and intestinal development 
(Rahmani et al. 2019).
Osteochondral organoids
Osteochondral organoids were manufactured from mouse 
induced pluripotent stem cells to study the interactions 
between bone and cartilage tissues, understanding the 
interaction of which is of particular importance for sol-
ving the problem of osteoarthritis. Organoids were grown 
by time-dependent sequential exposure to growth fac-
tors, transforming growth factor β-3 (TGF-β3) and bone 
morphogenetic protein 2 (BMP2) to reproduce bone de-
velopment by endochondral ossification. As a result, car-
tilaginous regions and calcified bone regions within the 
organoid were obtained, with the potential for screening 
drugs intended for the treatment of joint diseases and stu-
dying the genetic risk in patients or the specifics of a di-
sease development (O’Connor et al. 2020).
Use of organoids as test systems for 
drugs screening
One of the key reasons to establish and use 3D cellular 
constructs is their potential impact on the new drugs de-
velopment. When used in organoid research, candidate 
compounds are more efficiently screened prior to in vivo 
testing, which increases the chances of success and redu-
ces drug development costs.
Organoid models not only make it possible to perform 
effective testing on target tissues the drug is aimed at, but 
also to reveal the possible toxic effect of the substance on 
vital organs: heart, liver, lungs, which allows preventing 
unexpected complications that can lead to serious side ef-
fects (Rajkumar et al. 2013; Devarasetty et al. 2018; Mi-
randa et al. 2018).
Most studies performed using microphysiological sys-
tems are aimed to study the toxicity of drugs, and only in 
some cases to identify their effectiveness (Denisuk et al. 
2015; Truskey 2018; Korokin et al. 2019).
Cardiac models for toxicity research should mimic the 
electrical activity of cardiomyocytes and be sensitive to 
cytotoxic effects that damage heart muscle cells. Almost 
all models of cardiac organoids use cardiomyocytes as 
the main components of 3D structures, but they use them 
in different ways (Devarasetty et al. 2018; Korokin et al. 
2020). For example, by using organoids it was shown that 
adrenaline increased the heart rate, but the developing 
effect can be blocked by the addition of propranolol. It 
was revealed that digoxin and isoproterenol have a mo-
dulating effect on the strength and timing of contractions. 
Numerous proarrhythmic compounds have been tested, 
and concentration-dependent and reversible contraction 
changes were demonstrated (Devarasetty et al. 2018).
Various drugs that affect the strength and duration of 
cardiac muscle contractility have a similar effect on the 
microphysiological systems consisting of cardiomyocytes 
derived from iPSCs (beat frequency or contractile stress) 
(Mathur et al. 2015; Huebsch et al. 2016; Lind et al. 2017; 
Truskey 2018).
A significant number of drugs with known hepatic 
toxicity have been tested on liver organoids. Currently, 
the gold standard is the inclusion of primary human he-
patocytes into 3D constructs that will be used for drugs 
screening (Messner et al. 2013).
Vernetti et al. characterized the functional association 
of microphysiological systems, the joint work of the sto-
mach and liver, which metabolized toxic terfenadine to its 
non-toxic and vasoactive form fexofenadine, which could 
not penetrate the blood-brain barrier (Vernetti et al. 2017).
An ideal lung model for drug screening and toxicity 
testing should provide information on the characteristics 
of gas exchange, respiration rate and/or cell viability. 
Skardal et al. formed lung organoids by layering lung epit-
helial cells on fibroblasts and endothelial cells. The TEER 
sensor was integrated into the system to demonstrate that 
the organoid response was similar to that of the organ in 
vivo. The study showed that when exposed to bleomycin, 
a chemotherapeutic agent used to treat lymphoma, pul-
monary organoids secreted interleukin 8, a lung-specific 
marker of inflammation (Skardal et al. 2017).
Brain organoids were cultured in the lumen of microf-
luidic channels to provide perfusion, and then the res-
ponse to nicotine was tested. Inhibition of the differen-
tiation and organization of organoids was revealed upon 
exposure to nicotine concentrations recorded in smoking 
abusers, which, according to the authors, may account for 
impaired fetal neurogenesis in smoking mothers (Truskey 
2018; Wang et al. 2018).
Most drugs are designed to treat specific symptoms and 
disease etiology, so testing is performed on 3D models of 
the disease of interest, sometimes referred to as “disease-
in-a-dish” or “disease-on-a-chip” models (Devarasetty et 
al. 2018). For example, organoids were created that simu-
lated liver fibrosis that can be used to screen drugs for the 
treatment of liver fibrosis (Devarasetty et al. 2018).
Leite et al. cultivated hepatocyte-like cells (HepaRG) 
and primary hepatic stellate cells (HSCs) in the spheroid 
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format, after which the spheroids were treated with profi-
brotic compounds – allyl alcohol and methotrexate, which 
led to the activation of HSCs and the generation of fibro-
sis (Leite et al. 2016). Prestigiacomo et al. characterized 
a similar spheroid-based system, in which, in addition to 
HSCs and HepaRGs, Kupffer cells were included. Sp-
heroids were treated with transforming growth factor-b1, 
methotrexate and thioacetamide to induce the activation 
of both HSCs and Kupffer cells for the development of 
fibrosis (Prestigiacomo et al. 2017).
The use of human intestinal organoids grown from 
crypt fragments was characterized for the study of cystic 
fibrosis (CF), caused by mutations in the cystic fibrosis 
transmembrane conductance regulator gene (CFTR) that 
encodes epithelial anion channels (Dekkers et al. 2016). 
Organoids have been used in preclinical studies to iden-
tify and develop CFTR modulating drugs and to study the 
mechanisms associated with differences in CFTR functi-
oning (Van Mourik et al. 2019). In a study on organoids 
by Dekkers et al., CFTR mutations and additional patient 
specific genetic traits were shown to modify the response 
to CFTR modulators (Dekkers et al. 2016). Vallier et al. 
also showed that iPSCs obtained from CF patients diffe-
rentiated into hepatic cholangiocytes and could serve as 
an in vitro model of CF (Sampaziotis et al. 2015; Lancas-
ter and Huch 2019).
Benam et al. created a lung organoid and integrated it 
into a microfluidic chip containing epithelial and endothe-
lial cells. The 3D construct was used to stimulate asthma 
and chronic obstructive pulmonary disease. Interleukin 
13 (IL-13) treatment led to an increased number of goblet 
cells and increased secretion of granulocyte-colony stimu-
lating factor (G-CSF) and granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF), two inflammatory cyto-
kines, roughly corresponding to the asthmatic response 
(Benam et al. 2016; Devarasetty et al. 2018). Such sys-
tems are based on cell-cell and cell-matrix interactions and 
are ideal for use in 3D organoids, since the disease state is 
directly related to changes in tissue microenvironment and 
cellular phenotype, which are best reflected in 3D.
Currently, a number of different tumor organoids and 
“tumor-on-a-chip” systems have been developed. Orga-
noids have been successfully grown from primary tumors 
of the colon, prostate, breast, and pancreas. These “tumo-
roids” have evolved into preclinical models that can pre-
dict a patient’s individual response to treatment (Clevers 
2016; Li and Izpisua Belmonte 2019). Patient-derived tu-
mor organoids are better at replicating native tumors and 
potentially better models for identifying and testing new 
anticancer drugs (Drost and Clevers 2018; Vlachogiannis 
et al. 2018). For example, when drug screening using or-
ganoids of primary human liver cancer, ERK inhibition 
has been identified as a potential therapeutic approach for 
treating primary liver cancer (Broutier et al. 2017; Drost 
and Clevers 2018).
Boretto et al. manufactured and cultivated for a long 
time organoids that simulate a wide range of endometrial 
pathologies: from endometriosis and hyperplasia to low 
and high grade cancers. Organoids that model endometrio-
sis have been shown to exhibit disease-specific features 
and cancer-related mutations. Organoids established from 
tumor-affected endometrium accurately characterize can-
cer subtypes, replicate altered tumor surfaces, and demon-
strate patient-specific drug responses (Boretto et al. 2019).
Driehuis et al. described the creation of 30 patient-de-
rived organoid lines (PDOs) from tumors arising in the 
pancreas and distal bile duct. PDOs mimic tumor histo-
logy and contain genetic changes typical of pancreatic 
cancer. The testing of 76 therapeutic agents, including 
chemotherapy drugs currently used for the treatment of 
pancreatic ductal adenocarcinoma (PDAC), has been 
characterized, which has revealed sensitivity to drugs not 
currently used in the clinic, which emphasizes the impor-
tance of an individualized approach to effective cancer 
treatment. The PRMT5 inhibitor EZP015556 has been 
shown to have an effect on both MTAP (a gene common-
ly lost in pancreatic cancer) -negative and MTAP-positive 
tumors (Driehuis et al. 2019).
An important advantage of using organoid techno-
logy for drug development is that both healthy and tumor 
tissues can be used to establish organoids, allowing for 
screening drugs that specifically target tumor cells while 
leaving healthy cells intact. This approach can lead to a 
decrease in the damaging effects of drugs on the organism 
(Drost and Clevers 2018).
The ability to create organoids from individual tumors 
will allow introducing a huge clinical variety of tumor tis-
sues into the laboratory. In this connection, considerable 
efforts are being made to make organoids available to the 
scientific community, including by creating “living bio-
banks” (for example, the Hubrecht Organoid Technology 
(HUB) “living” biobank). Thus, the HUB contains about 
1,000 tumor cell models, including tumors of the breast, 
lungs, pancreas, and prostate cancer (Weeber et al. 2017; 
Tuveson and Clevers 2019).
In general, it is believed that the reliability of the data 
obtained through organoid-based drug screening will in-
crease as screening and data analysis methods become 
more standardized (Driehuis et al. 2020).
Using organoids to model 
infectious diseases and 
study adaptive responses of 
microorganisms when interacting 
with the host
Infectious diseases, predominantly diarrhea, AIDS, tuber-
culosis, and malaria, kill about 20 million people every 
year. The so-called “successful pathogens” overcome the 
barriers of innate and acquired immunity due to the pre-
sence of evolutionarily formed mechanisms, including 
bacteria evading recognition; creation of obstacles to 
phagocytosis and intracellular killing; the use of secretory 
systems in the form of a “syringe” for the introduction of 
dysregulating substances into the host cells; suppression 
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or stimulation of the inflammatory response; activation 
of inhibitory receptors to suppress the respiratory burst 
in the phagosome; the effect on inflammasomes and the 
subsequent decrease in the synthesis of pro-inflammatory 
cytokines; the ability to stimulate the synthesis and se-
cretion of cytokines that suppress the innate immune res-
ponse; disruption of the functioning of key molecules of 
intracellular signaling pathways; impact on the processes 
of apoptosis and autophagy, accompanied by survival and 
replication within host cells (Garib and Rizopulu 2012).
In addition, pathogens (infectious diseases causative 
agents) have adapted to recognize the specific structures 
of the host organism, polarity, and changes in the stimuli 
of the local environment (pH, temperature, oxygen con-
tent, nutrients, hormones, physiological forces) in order 
to timely activate specific damaging programs during the 
stages of infection (Nickerson et al. 2004; Alsharif et al. 
2015; Fang et al. 2016; Persat 2017).
The study of the peculiarities of the interaction of host 
organisms and the pathogen will reveal the evasion me-
chanisms of pathogenic microorganisms and use them in 
order to create original vaccines and fundamentally new 
drugs for the correction of impaired functions of the im-
mune system in numerous diseases, such as malignant 
neoplasms, autoimmune and allergic diseases, as well as 
infectious diseases (Garib and Rizopulu 2012).
Organoids are now widely used to study the interaction 
of host cells with microorganisms, including viruses, bac-
teria, and parasites (Fatehullah et al. 2016; Barrila et al. 
2018; Duque-Correa et al. 2020). The use of organoids al-
lows the reconstruction of a three-dimensional micro-en-
vironment characteristic of the host organism and regu-
lating infection, which includes multicellular complexes, 
commensal microbiota, gas exchange, and nutrient gra-
dient, as well as physiologically relevant biomechanical 
forces (for example, shear stress, tension, compression), 
the reconstruction of which is one of the key tasks in 3D 
microenvironment modeling (Barrila et al. 2018).
It has been revealed that enteric microbes effect the 
pathogenesis of a wide range of intestinal immune-medi-
ated diseases and systemic disorders (Hsiao et al. 2013). 
Various pathogens have been studied using 3D enteroid/
colonoid/organoid models, including Salmonella, C. dif-
ficile, EHEC, EPEC, enterotoxic E. coli (ETEC), norovi-
ruses, rotaviruses, enteroviruses, Toxoplasma gondii, and 
coronaviruses (Zhang et al. 2014; Engevik et al. 2015; 
Forbester et al. 2015; Bartfeld 2016; In et al. 2016a; Hill 
and Spence 2017; Karve et al. 2017; Barrila et al. 2018).
Induced human intestinal organoids (iHIOs) are a sui-
table model for studying the pathophysiology of human 
viral gastroenteritis caused by human rotavirus (HRV) or 
norovirus (HuNoV) (Yin et al. 2015; Leslie and Young 
2016; Zou et al. 2017; Blutt et al. 2018). The use of iHIOs 
obtained from the cultivation of human stem cells was 
described for modeling the infectious process caused by 
rotaviruses (Finkbeiner et al. 2012) during co-cultivation 
of HIOs with rotavirus, the virus was shown to affect hu-
man IECs, mainly enterocytes and enteroendocrine cells, 
as well as mesenchymal cell lines (Rahmani et al. 2019).
Organoid models are used to study bacterial patho-
genesis, including Vibrio cholerae, Clostridium diffici-
le, Shigella, which infect intestinal organoids of murine, 
bovine, porcine and human origin (In et al. 2016b; Dutta 
and Clevers 2017; Dutta et al. 2017; Barrila et al. 2018; 
Derricott et al. 2019; Duque-Correa et al. 2020), as well as 
Helicobacter pylori, which colonizes stomach organoids 
(Duque-Correa et al. 2020). In addition, the participation 
of bacteria in the formation of adenocarcinoma in the gal-
lbladder was investigated using gallbladder organoids in-
fected with Salmonella (Dutta and Clevers 2017; Dutta et 
al. 2017). Obligate anaerobic bacteria, such as Clostridium 
difficile (C. difficile) survive when cultured in the cavity of 
HIOs. Such studies shed light on the potential of intestinal 
organoids for studying anaerobic bacteria, which are abun-
dant in the gut microbiome (Rahmani et al. 2019).
Intestinal enteroids are also successfully cultured with 
such bacteria as Salmonella enterica serovar Typhimuri-
um, which leads to the development of gastroenteritis in 
humans, Escherichia coli (E. coli), Lactobacillus reuteri 
D8, the presence of the latter two not only enhances the 
growth of enteroids, but also reduces damage caused by 
TNFα, which leads to ICS regeneration (Hou et al. 2018). 
It has also been demonstrated that lactobacilli are capa-
ble of exerting a modulating effect on the host’s immune 
system. However, epithelial-commensal bacterial interac-
tions with the host organism have been hardly studied due 
to limited access to the tissues of the human small intes-
tine (Son et al. 2020). Some lactobacilli species have de-
veloped the ability to stimulate the generation of reactive 
oxygen species (ROS) in epithelial cells, which leads to 
the proliferation of intestinal epithelial cells through pro-
cesses requiring the catalytic action of Nox1. Further stu-
dies showed that feeding the same species of lactobacilli 
improves wound healing and promotes the restoration of 
the intestinal epithelium after mechanical damage by me-
ans of the mechanisms that were dependent on the formyl 
peptide receptor, ROS and Nox1. However, little is known 
about the cellular signaling pathways that are activated in 
response to lactobacillus-induced ROSs in the intestinal 
epithelium and mediate the transmission of bacterial-ini-
tiated signals to subepithelial compartments (Darby et 
al. 2020). Studies have shown that lactobacilli (Lactoba-
cillus) can effectively prevent the invasion of pathogens 
and protect the integrity of the intestinal mucosal barrier. 
However, the probiotic role of Lactobacillus mainly me-
ans the induction of low pH, secretion of antimicrobial 
peptides, and maintaining tight junctions (Lu et al. 2020).
An infection caused by an uropathogen, Enterococ-
cus faecalis, has been studied using urothelial organoids 
(Horsley et al. 2018). More recently, fallopian tube or-
ganoids have served as a model to investigate long-term 
effects of the infection caused by Chlamydia trachoma-
tis (Ctr) on human epithelium, which can lead to ova-
rian cancer (Kessler et al. 2019). It was revealed that 
the Ctr-induced infection activated the LIF signaling 
pathway, which is important for regulating the ability of 
organoid component cells to maintain an undifferentia-
ted stemness. Infected organoids showed a less differen-
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tiated phenotype, which was confirmed by the increased 
efficiency of organoid formation. Moreover, Ctr incre-
ases DNA hypermethylation, which is an indicator of 
accelerated molecular aging (Kessler et al. 2019).
The complete life cycle of Cryptosporidium parvum can 
be modeled in murine and human small intestine (Heo et al. 
2018; Wilke et al. 2019) and lung organoids (Heo et al. 2018). 
Lung organoids successfully replicate C. parvum-induced in-
fections of the respiratory tract that develop in immune com-
petent and non-immune organisms (Heo et al. 2018).
Conclusion
Thus, the creation of three-dimensional cell structures that re-
produce the structural and functional characteristics of tissue 
in vivo makes it possible to study biology of the body’s deve-
lopment, the features of intercellular interaction under normal 
nicotine physiological conditions and pathology, screening 
drugs and co-cultivating with viruses, bacteria and parasites.
Table 1 shows the features of using various 3D cell 
structures in pharmacological research.
Despite the fact that the issues of vascularization of 
organoid systems, modeling intercellular communicati-
on with populations of stromal cells, and standardization 
of the procedure for creating 3D tissue-engineered con-
structs remain unresolved, organoid systems have great 
potential and provide unprecedented opportunities for im-
proving human health.
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Table 1. Using Different Organoid Systems in Drug Screening Research.
3D Model Modifications Using for drug screening, including therapies tested Refs
Brain organoids Organ-on-a-chip Study of the effect of nicotine on the processes of neurogenesis Truskey 2018; Wang et 
al. 2018.
Organoids derived from primary tumors Anti-cancer drug screening Truskey 2018; Wang et 
al. 2018
Lung organoids Organoids derived from primary lung tumor Anti-cancer drug screening Sachs et al. 2019
Layering of lung epithelial cells on fibroblasts 
and endothelial cells, adding a sensor to the 
TEER system
Study of the effect of bleomycin on the secretion of 
inflammatory markers
Skardal et al. 2017
Organ-on-a-chip, models of asthma and chronic 
obstructive pulmonary disease
Interleukin 13 (IL-13) exposure, study of asthmatic response Benam et al. 2016; 
Devarasetty et al. 2018
Heart organoids Cardiac organoid models with cardiomyocytes as 
major components
Study of the effect of adrenaline, digoxin, isoproterenol and a 
variety of proarrhythmic compounds on the strength and timing 
of contractions
Devarasetty et al. 2018
Microphysiological systems consisting of 
cardiomyocytes derived from iPSCs
Study of the effect of drugs on beat frequency or contractile 
stress
Mathur et al. 2015; 
Huebsch et al. 2016; Lind 
et al. 2017; Truskey 2018
Mammary gland 
(breast) organoids
Organoids from primary breast tumor – 
“tumoroids”
Anti-cancer drug screening Sachs et al. 2018; levers 
2016; Li and Izpisua 
Belmonte 2019
Liver 3D constructs Liver organoids, including primary human 
hepatocytes
Screening liver-toxic drugs Messner et al. 2013
Organoids grown from a liver tumor Anti-cancer drug screening, search for therapeutic approaches Broutier et al. 2017; Drost 
and Clevers 2018
Functional microphysiological systems that 
combine stomach and liver organoids
Study of the metabolism of toxic terfenadine to its non-toxic 
and vasoactive form fexofenadine
Vernetti et al. 2017
Formation of spheroids from hepatocyte-like 
cells (HepaRG) and primary hepatic stellate cells 
(HSCs) (and possibly Kupffer cells), followed by 
the generation of a fibrotic state
Effect of transforming growth factor-b1, methotrexate and 
thioacetamide to induce simultaneous activation of HSCs and 
Kupffer cells for the development of fibrosis
Leite et al. 2016; 
Prestigiacomo et al. 2017
Pancreas organoids 30 patient-derived organoid lines (PDOs) from 
tumors originating in the pancreas and distal bile 
duct, “tumoroids”
Testing of 76 therapeutic agents was characterized, including 
chemotherapy drugs currently used to treat pancreatic ductal 
adenocarcinoma (PDAC)
Driehuis et al. 2019; 
Clevers 2016; Li and 
Izpisua Belmonte 2019
Stomach organoids Organoids derived from primary stomach tumors Anti-cancer drug screening Yan et al. 2018;  Driehuis 
et al. 2019
Intestinal organoids Intestinal tumor-derived organoids Anti-cancer drug screening Yan et al. 2018
Intestinal organoids grown from crypt fragments 
as a model for the study of cystic fibrosis
Organoids were used in preclinical studies to identify and 
develop CFTR modulating drugs and to study the mechanisms 
associated with differences in CFTR functioning
Dekkers et al. 2016; Van 
Mourik et al. 2019
iPSCs obtained from CF patients differentiated 
into hepatic cholangiocytes, CF in vitro model




Organoids grown from primary tumors Anti-cancer drug screening Tamura et al. 2018
Organoids that model a wide range of 
endometrial pathologies: from endometriosis and 
hyperplasia to low and high grade cancers
Organoids that model endometriosis were shown to exhibit 
disease-specific features and cancer-related mutations. 
Organoids formed from tumor-affected endometrium accurately 
characterize cancer subtypes, replicate altered tumor surfaces, 
and demonstrate patient-specific drug responses
Boretto et al. 2019
Bladder, prostate 
organoids
Organoids grown from primary tumors Anti-cancer drug screening Gao et al. 2014; Lee et al. 
2018; Driehuis et al. 2020; 
Kim et al. 2020
Colorectal organoids Organoids grown from a primary tumor of the 
colon
Anti-cancer drug screening Van de Wetering 2015; 
Clevers 2016; Li and 
Izpisua Belmonte 2019
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